INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)	9 Months Ended		219 Months Ended
	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014
Cash Flows From Operating Activities:
Net income/(loss)	$ (2,385,273)	$ (4,999,736)	$ (365,113,155)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	280,743	349,047	10,653,001
Minority interest share of loss			(3,038,185)
Reduction of notes receivable - common stock in exchange for services rendered			423,882
Write-off of uncollectible notes receivable - common stock			391,103
Write-off of deferred offering costs			3,406,196
Write-off of abandoned patents			1,353,976
Gain on disposal of property and equipment	(188,869)	(1,036,865)	(3,217,504)
Loss on extinguishment of debt			14,134,068
Common stock issued as employee compensation			4,011,938
Amortization of options and option modifications as stock compensation	262,871	613,375	4,511,851
Common stock issued for services rendered	360,500	223,692	15,260,200
Amortization of prepaid services in conjunction with common stock issuance			138,375
Non-cash compensation expense			45,390
Stock options and warrants issued for services rendered			7,956,723
Issuance of warrants as additional exercise right inducement			21,437,909
Preferred stock issued for services rendered			100
Treasury stock redeemed for non-performance of services			(138,000)
Amortization of deferred debt issuance costs and loan origination fees			2,405,629
Amortization of discount on convertible debentures			38,345,592
Common stock issued for interest on convertible debentures & preferred stock	522,450	663,930	2,652,104
Interest on short-term advance			22,190
Founders' shares transferred for services rendered			353,506
Fees in connection with refinancing of debt			113,274
Warrant repricing costs			3,198,604
Change in fair value of derivative liabilities	(1,360,818)	1,092,504	2,495,418	[1]
Changes in operating assets and liabilities (excluding the effects of acquisition):
Accounts receivable			(15,047)
Miscellaneous receivables			43,812
Inventory			(20,091)
Other current assets	51,003	154,586	(7,748)
Accounts payable and accrued expenses	(300,383)	212,595	14,847,113
Deferred revenue	(1,181)	(33,504)	217,869
Other, net			110,317
Net Cash Used in Operating Activities	(2,758,957)	(2,760,376)	(223,019,589)
Cash Flows From Investing Activities:
Purchase of property and equipment			(4,809,439)
Proceeds from sale of property and equipment	883,780	1,762,954	7,601,113
Costs incurred for patents	(61,812)	(51,717)	(2,980,806)
Change in restricted cash			512,539
Proceeds from maturity of short term investments			195,242,918
Purchases of short-term investments			(195,242,918)
Cash received in conjunction with merger			82,232
Advances to Antigen Express, Inc.			(32,000)
Increase in officers' loans receivable			(1,126,157)
Change in deposits			(652,071)
Change in notes receivable - common stock			(91,103)
Change in due from related parties			(2,222,390)
Other, net			89,683
Net Cash Provided By (Used in) Investing Activities	821,968	1,711,237	(3,628,399)
Cash Flows From Financing Activities:
Proceeds from short-term advance			325,179
Repayment of short-term advance			(347,369)
Proceeds from issuance of long-term debt		828,543	6,396,335
Repayment of long-term debt	(606,806)	(1,832,170)	(9,502,770)
Repayment of obligations under capital lease			(83,002)
Change in due to related parties			154,541
Proceeds from exercise of warrants, net	2,301,944	780,704	49,875,429
Proceeds from exercise of stock options	526	1,057	5,009,500
Proceeds from minority interest investment			3,038,185
Proceeds from issuance of preferred stock, net	2,770,000	1,450,000	21,690,000
Redemption of SVR preferred stock			(100)
Proceeds from issuance of convertible debentures, net			40,704,930
Payment of costs associated with convertible debentures			(722,750)
Repayments of convertible debentures			(5,142,424)
Purchase of treasury stock			(483,869)
Proceeds from issuance of common stock, net			120,576,242
Purchase and retirement of common stock			(497,522)
Net Cash Provided by Financing Activities	4,465,664	1,228,134	230,990,535
Effect of Exchange Rates on Cash	(18,894)	(18,723)	(123,812)
Net Increase in Cash and Cash Equivalents	2,509,781	160,272	4,218,735
Cash and Cash Equivalents, Beginning of Period	1,708,954	246,309
Cash and Cash Equivalents, End of Period	4,218,735	406,581	4,218,735
Supplemental Disclosure of Cash Flow Information
Cash paid during the period for Interest	35,542	251,177
Disclosure of non-cash investing and financing activities:
Par value of common stock issued in conjunction with cashless exercise of warrants		29,185
Issuance of common stock as repayment of convertible debentures and advance payments	$ 522,450	$ 663,930

[1] Includes $5,981,403 as adjustment related to the adoption of FASB ASC Topic 815 in "Cumulative from November 2, 1995 (Date of Inception) to January 31, 2014" column. See Note 10 - Derivative Warrant Liability.